JIMMY SPELTS: Open Payments
NPI 1104423946 · CHESAPEAKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$341 in 18 payments from 9 companies in 2025. Trend: 2023 $414 · 2024 $809 · 2025 $341
Food & beverage: $341
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 4 | $69 |
| ABBVIE INC. | 4 | $67 |
| Neurocrine BioSciences, Inc. | 2 | $53 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| Lundbeck LLC | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Tris Pharma Inc | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
Products named: Qelbree, VRAYLAR, REXULTI, INGREZZA, CAPLYTA, Auvelity, Dyanavel XR, UZEDY.
Industry payments across VA — which companies pay providers there.
